Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 13/20 | 0.50 |
| ▸ | CCND1 | P24385 | 13/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 3/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | TACR2 | P21452 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1971783 | 0.94 | CDK4 (0.46) | CDK4CCND1CDK2TACR2HDAC1 | |
| SCHEMBL1969032 | 0.92 | CDK4 (0.50) | CDK4CCND1CDK2SIRT1 | |
| SCHEMBL1972018 | 0.90 | CDK4 (0.54) | CDK4CCND1NAMPTCDK2GPR84 | |
| SCHEMBL1971216 | 0.88 | CDK4 (0.43) | CDK4CCND1CDK2TACR2 | |
| SCHEMBL1967560 | 0.87 | CDK4 (0.49) | CDK4CCND1NAMPTCDK2GPR84 | |
| SCHEMBL1966311 | 0.87 | CDK4 (0.48) | CDK4CCND1CDK2 | |
| SCHEMBL1973622 | 0.86 | CDK4 (0.51) | CDK4CCND1NAMPTCDK2GPR84 | |
| SCHEMBL1969807 | 0.83 | CDK4 (0.52) | CDK4CCND1NAMPTCDK2GPR84 | |
| SCHEMBL1970863 | 0.82 | CDK4 (0.50) | CDK4CCND1CDK2TACR2 | |
| SCHEMBL1969670 | 0.81 | CDK4 (0.53) | CDK4CCND1CDK2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | claimed |
| EP-2334643-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | Actelion Pharmaceuticals Ltd. (CH) | 2011-06-22 | — | — | EP | claimed |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| EP-2334643-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | Actelion Pharmaceuticals Ltd. (CH) | 2011-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | CDK4 3031/4885CCND1 3178/4885NAMPT 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.